SS
MNPR icon

SBI Securities’s Monopar Therapeutics MNPR Stock Holding History

SBI Securities’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$2.2K – 4175
2024
Q4 		$2.2K Buy
+100
New +$1.68K ﹤0.01% 2275

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SBI Securities's MNPR Position: Q1 2025 in Review

SBI Securities sold out of Monopar Therapeutics (MNPR) in Q1 2025, closing a stake of 100 shares — an estimated $2.2K sold.

SBI Securities first reported a position in MNPR in Q4 2024 and held it in 1 quarter. The position peaked at $2.2K in Q4 2024. 35 funds tracked by Wall St. Rank hold MNPR as of Q1 2025.

  • SBI Securities reported no remaining Monopar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SBI Securities sold 100 Monopar Therapeutics shares in Q1 2025, an estimated $2.2K.
  • SBI Securities first reported a position in Monopar Therapeutics in Q4 2024 and held it in 1 quarter.
  • SBI Securities's Monopar Therapeutics position peaked at $2.2K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2025.

Based on SBI Securities's 13F filing for Q1 2025, filed 2 May 2025.